SCHEMBL21144240

SCHEMBL21144240

CCOC(=O)c1cc(NC2CC(F)(F)C2)nc(-n2nc(C)cc2C)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 6/20 0.48
KDM4E B2RXH2 5/20 0.48
NR2F2 P24468 2/20 0.48
MAPT P10636 2/20 0.48
MAPK1 P28482 1/20 0.48
ALDH1A1 P00352 4/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
LMNA P02545 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
XBP1 P17861 2/20 0.48
PPP1CA P62136 2/20 0.48
S1PR2 O95136 1/20 0.48
KCNN2 Q9H2S1 1/20 0.47
KCNN3 Q9UGI6 1/20 0.47
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TSHR P16473 2/20 0.44
ALOX15 P16050 5/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19687176 0.93 NPSR1 (0.48) NPSR1KDM4ENR2F2MAPTMAPK1
SCHEMBL19687165 0.91 NPSR1 (0.51) NPSR1KDM4ENR2F2MAPTMAPK1
SCHEMBL21143905 0.90 NPSR1 (0.52) NPSR1KDM4ENR2F2MAPTMAPK1
SCHEMBL19687166 0.84 KCNN2 (0.48) NPSR1KDM4ENR2F2MAPTMAPK1
SCHEMBL21143802 0.82 NPSR1 (0.44) NPSR1KDM4ENR2F2MAPTMAPK1
SCHEMBL19686499 0.82 KCNN2 (0.52) NPSR1KDM4ENR2F2MAPTMAPK1
SCHEMBL19687168 0.81 KCNN2 (0.53) NPSR1KDM4ENR2F2MAPTMAPK1
SCHEMBL19686434 0.80 KCNN2 (0.53) NPSR1KDM4EMAPTMAPK1ALDH1A1
SCHEMBL21143794 0.79 KCNN2 (0.52) NPSR1ALDH1A1LMNAKCNN2KCNN3
SCHEMBL31127085 0.79 KCNN2 (0.52) NPSR1ALDH1A1LMNAKCNN2KCNN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 NPSR1 993/4885KDM4E 1648/4885NR2F2 2755/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 NPSR1 993/4885KDM4E 1648/4885NR2F2 2755/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 NPSR1 993/4885KDM4E 1648/4885NR2F2 2755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.